TERN-601
FALCON
Terns, Inc · Phase 2 · Completed · Enrollment 167
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| TERN-601 250 mg | n/r | n/r | n/r | n/r |
| TERN-601 500 mg (slow titration) | n/r | n/r | n/r | n/r |
| TERN-601 500 mg | n/r | n/r | n/r | n/r |
| TERN-601 750 mg | n/r | n/r | n/r | n/r |
| Matching Placebo | n/r | n/r | n/r | n/r |
Not shown
- TERN-601 250 mg: endpoint not reported
- TERN-601 500 mg (slow titration): endpoint not reported
- TERN-601 500 mg: endpoint not reported
- TERN-601 750 mg: endpoint not reported
- Matching Placebo: endpoint not reported